Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables

Novo has struck a 1.17 billion euro ($1.3 billion) deal to combine Nanexa’s long-acting injectable drug delivery platform with its obesity and Type 2 diabetes drugs.